Clinical and Microbiological Characteristics of Aspergillosis at a Chinese Tertiary Teaching Hospital

References

• Dellière S, Dudoignon E, Fodil S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect. 2020;27(5):790.e1–5. doi:10.1016/j.cmi.2020.12.005
   Web of Science ®Google Scholar
• Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020;24(1):299. doi:10.1186/s13054-020-03046-7
   Web of Science ®Google Scholar
• Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA)-from immunology to treatment. J Fungi. 2020;6(2). doi:10.3390/jof6020091
   Web of Science ®Google Scholar
• Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17–29. doi:10.1016/j.blre.2016.09.002
   PubMed Web of Science ®Google Scholar
• Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis. 2015;34(7):1289–1301. doi:10.1007/s10096-015-2374-1
   Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12(5):850–858. doi:10.1002/lt.20690
   Web of Science ®Google Scholar
• Ahmadikia K, Aghaei Gharehbolagh S, Fallah B, et al. Distribution, prevalence, and causative agents of fungal keratitis: a systematic review and meta-analysis (1990 to 2020). Front Cell Infect Microbiol. 2021;11:698780. doi:10.3389/fcimb.2021.698780
   Web of Science ®Google Scholar
• Bongomin F, Asio LG, Olum R, Denning DW. Intravenous therapy for chronic pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2020;63(9):921–927. doi:10.1111/myc.13131
   Web of Science ®Google Scholar
• Houbraken J, de Vries RP, Samson RA. Modern taxonomy of biotechnologically important Aspergillus and Penicillium species. Adv Appl Microbiol. 2014;86:199–249. doi:10.1016/b978-0-12-800262-9.00004-4
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B. Susceptibility testing of fungi to antifungal drugs. J Fungi. 2018;4(3). doi:10.3390/jof4030110
   Web of Science ®Google Scholar
• Vermeulen E, Maertens J, De Bel A, et al. Nationwide surveillance of azole resistance in aspergillus diseases. Antimicrob Agents Chemother. 2015;59(8):4569–4576. doi:10.1128/aac.00233-15
   PubMed Web of Science ®Google Scholar
• Deng S, Zhang L, Ji Y, et al. Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China. Emerg Microbes Infect. 2017;6(12):e109. doi:10.1038/emi.2017.97
   PubMed Web of Science ®Google Scholar
• Su H, Zhu M, Tsui CK, et al. Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China. Antimicrob Agents Chemother. 2021;65(5). doi:10.1128/aac.02546-20
   Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Xu X, Naseri A, Houbraken J, et al. Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran. Sci Rep. 2021;11(1):6808. doi:10.1038/s41598-021-86038-z
   Web of Science ®Google Scholar
• Zhang L, Wang X, Houbraken J, et al. Molecular identification and in vitro antifungal susceptibility of aspergillus isolates recovered from otomycosis patients in Western China. Mycopathologia. 2020;185(3):527–535. doi:10.1007/s11046-020-00448-7
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Clinical and Laboratory Standards Institute; 2017:1–62.
   Google Scholar
• Cadena J, Thompson GR, Patterson TF. Aspergillosis: epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 2021;35(2):415–434. doi:10.1016/j.idc.2021.03.008
   PubMed Web of Science ®Google Scholar
• Barati B, Okhovvat SA, Goljanian A, Omrani MR. Otomycosis in central Iran: a clinical and mycological study. Iran Red Crescent Med J. 2011;13(12):873–876. doi:10.1159/000249653
   Web of Science ®Google Scholar
• Chan JF, Lau SK, Wong SC, et al. A 10-year study reveals clinical and laboratory evidence for the ‘semi-invasive’ properties of chronic pulmonary aspergillosis. Emerg Microbes Infect. 2016;5(4):e37. doi:10.1038/emi.2016.31
   Web of Science ®Google Scholar
• Yang X, Chen W, Liang T, et al. A 20-year antifungal susceptibility surveillance (from 1999 to 2019) for Aspergillus spp. and proposed epidemiological cutoff values for aspergillus fumigatus and aspergillus flavus: a study in a tertiary hospital in China. Front Microbiol. 2021;12:680884. doi:10.3389/fmicb.2021.680884
   PubMed Web of Science ®Google Scholar
• Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the north eastern part of Haryana. Int J Pediatr Otorhinolaryngol. 2010;74(6):604–607. doi:10.1016/j.ijporl.2010.03.001
   Web of Science ®Google Scholar
• Danion F, Rouzaud C, Dureault A, et al. Why are so many cases of invasive aspergillosis missed? Med Mycol. 2019;57(Supplement_2):S94–S103. doi:10.1093/mmy/myy081
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl 1):S49–58. doi:10.1080/13693780400020113
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Y, Wu D, et al. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. Mycoses. 2021;64(4):445–456. doi:10.1111/myc.13233
   Web of Science ®Google Scholar
• Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004;209(2):104–110. doi:10.1159/000079593
   Web of Science ®Google Scholar
• English MP, Atkinson R. Onychomycosis in elderly chiropody patients. Br J Dermatol. 1974;91(1):67–72. doi:10.1111/j.1365-2133.1974.tb06718.x
   Web of Science ®Google Scholar
• Nkondjo Minkoumou S, Fabrizi V, Papini M. Onychomycosis in Cameroon: a clinical and epidemiological study among dermatological patients. Int J Dermatol. 2012;51(12):1474–1477. doi:10.1111/j.1365-4632.2012.05509.x
   Web of Science ®Google Scholar
• Hilmioğlu-Polat S, Metin DY, Inci R, Dereli T, Kilinç I, Tümbay E. Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey - A prospective study. Mycopathologia. 2005;160(2):125–128. doi:10.1007/s11046-005-6872-z
   Web of Science ®Google Scholar
• Das NK, Ghosh P, Das S, Bhattacharya S, Dutta RN, Sengupta SR. A study on the etiological agent and clinico-mycological correlation of fingernail onychomycosis in eastern India. Indian J Dermatol. 2008;53(2):75–79. doi:10.4103/0019-5154.41651
   Google Scholar
• Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol. 2009;47(Suppl 1):S261–70. doi:10.1080/13693780802247702
   PubMed Web of Science ®Google Scholar
• Tsang CC, Hui TW, Lee KC, et al. Genetic diversity of Aspergillus species isolated from onychomycosis and Aspergillus hongkongensis sp. nov., with implications to antifungal susceptibility testing. Diagn Microbiol Infect Dis. 2016;84(2):125–134. doi:10.1016/j.diagmicrobio.2015.10.027
   PubMed Web of Science ®Google Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses. 2009;52(3):206–222. doi:10.1111/j.1439-0507.2008.01642.x
   PubMed Web of Science ®Google Scholar
• Rychert J, Slechta ES, Barker AP, et al. Multicenter evaluation of the Vitek MS v3.0 system for the identification of filamentous fungi. J Clin Microbiol. 2018;56(2). doi:10.1128/jcm.01353-17
   Web of Science ®Google Scholar
• Dupont D, Normand AC, Persat F, Hendrickx M, Piarroux R, Wallon M. Comparison of matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of moulds in the routine microbiology laboratory. Clin Microbiol Infect. 2019;25(7):892–897. doi:10.1016/j.cmi.2018.10.013
   Web of Science ®Google Scholar
• Shin JH, Kim SH, Lee D, et al. Performance evaluation of VITEK MS for the identification of a wide spectrum of clinically relevant filamentous fungi using a Korean Collection. Ann Lab Med. 2021;41(2):214–220. doi:10.3343/alm.2021.41.2.214
   Web of Science ®Google Scholar
• Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol. 2016;33(2):63–75. doi:10.1016/j.riam.2016.04.001
   PubMed Web of Science ®Google Scholar
• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392. doi:10.1016/s1473-3099(17)30316-x
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 2018;51(3):333–339. doi:10.1016/j.ijantimicag.2017.09.002
   PubMed Web of Science ®Google Scholar
• Gupta AK, Renaud HJ, Quinlan EM, Shear NH, Piguet V. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021;22(2):149–157. doi:10.1007/s40257-020-00580-6
   PubMed Web of Science ®Google Scholar